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Abstract
Background: A non-inferiority (NI) trial is intended to show that the effect of a new treatment is not worse than the
comparator. We conducted a review to identify how NI trials were conducted and reported, and whether the standard
requirements from the guidelines were followed.
Methodology and Principal Findings: From 300 randomly selected articles on NI trials registered in PubMed at 5 February
2009, we included 227 NI articles that referred to 232 trials. We excluded studies on bioequivalence, trials on healthy
volunteers, non-drug trials, and articles of which the full-text version could not be retrieved. A large proportion of trials
(34.0%) did not use blinding. The NI margin was reported in 97.8% of the trials, but only 45.7% of the trials reported the
method to determine the margin. Most of the trials used either intention to treat (ITT) (34.9%) or per-protocol (PP) analysis
(19.4%), while 41.8% of the trials used both methods. Less than 10% of the trials included a placebo arm to confirm the
efficacy of the new drug and active comparator against placebo, and less than 5.0% were reporting the similarity of the
current trial with the previous comparator’s trials. In general, no difference was seen in the quality of reporting before and
after the release of the CONSORT statement extension 2006 or between the high-impact and low-impact journals.
Conclusion: The conduct and reporting of NI trials can be improved, particularly in terms of maximizing the use of blinding,
the use of both ITT and PP analysis, reporting the similarity with the previous comparator’s trials to guarantee a valid
constancy assumption, and most importantly reporting the method to determine the NI margin.
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Introduction
In the drug development process, the randomized controlled
trial (RCT) can have a superiority, equivalence or a non-inferiority
design. A superiority trial aims to demonstrate the superiority of a
new therapy compared to an active comparator or a placebo,
while an equivalence trial aims to demonstrate that a new therapy
is equivalent (within margins) to its active comparator. In non-
inferiority (NI) trials, the aim is to show that the new treatment is
not worse than the comparator, which typically is an active drug.
NI trials can be used in a situation when a new drug considered
has a similar efficacy profile as its comparator but may offer other
advantages over the existing drug such as a novel method of
administration or a better safety profile. In a regulatory setting, NI
trials can be used to provide primary, but indirect, evidence of
efficacy of a novel drug in cases where a placebo control treatment
is not ethically justified.[1,2]
Critics have pointed at various drawbacks of NI trials, questioning
whether they are really useful. Some argue that NI trials only benefit
pharmaceutical industry as they allow drugs without additional
clinical efficacy to enter the market.[3,4] However, as argued by
Jones et.al, in some cases the new treatment may have no direct
advantage but may present an alternative or second line therapy.[5]
From a methodological perspective, compared to superiority trials,
NI trials have methodological issues in design and analysis that can
influence proper inference. First, the value of blinding in NI trial is
under debate, especially if the endpoints are subjective.[6] In a
superiority trial, a blinded investigator who has a preliminary belief in
superiority of the test drug cannot manipulate the results to support
his belief. On the contrary, in an NI trial, the blinded investigator
with a preliminary belief in non-inferiority of the test drug can bias
the result by assigning similar ratings to the treatment responses of all
patients. Others argued that blinding is still important to show the
differences between drugs in NI trials.[7] Second, there are different
methods to determine the NI margin and there are debates on
whether the margin should be determined based on statistical or
clinical considerations. Third, although there is a degree of consensus
that non-inferiority should be shown for both the intention-to-treat
(ITT) and per-protocol (PP) analysis sets, it is not clear whether this
willbe conservative or anti-conservative in a particular situation.[6,7]
Fourth, a difficulty in interpreting NI trials is their lack of ability
to distinguish an effective drug from an ineffective drug i.e. assay
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is considered effective if it shows a significant treatment effect
compared with placebo. An additional placebo arm is recommended
to confirm assay sensitivity [2,6,9]. However, this is often impossible
due to ethical reasons. Last, the validity of the historical data that was
used as the reference for the current trial, i.e. constancy assumption, is
a critical point in the interpretation of NI trials. Related to the last
issue, the CONSORT statement has recommended authors to
mention whether the eligibility criteria, interventions and outcomes
are identical or very similar to any trial that established efficacy of the
reference treatment.[10] The effort is encouraged to support the
validity of the constancy assumption.
The ICH E9 [11], the ICH E10 [8], CHMP guidelines [12] and
the extension of the CONSORT statement on NI trials[10] are
the currently available guidelines for the appropriate conduct and
report of NI trials. We summarized the guidelines’ recommenda-
tions on the five methodological issues described above in Table 1.
Furthermore, we included the FDA draft guideline on NI trials
[13] in Table 1 for consideration. The draft FDA guideline is not
in effect yet and still open for changes (as per 18
th March 2010).
In this review, we described how published NI trials were
conducted and reported, and whether the standard requirements
from the guidelines were followed.
Methods
Search strategy and publication selection
We performed searches for NI trials in PubMed on 5 February
2009 and retrieved 669 articles as described in Figure 1. Subsequently,
based on pragmatic consideration rather than formal sample size
calculation, we used SPSS 16 to select a random sample of 300
articles. We subsequently excluded study design papers, reviews, trials
using healthy volunteers, non-drug trials, non-RCTs, and articles of
which the full-text version could not be retrieved. If one article
reported multiple trials, we analyzed the trials separately. If multiple
articles reported the result of one trial, we considered them as one
subject, and included only the first publication.
Data extraction
To extract relevant data, we created a standardized data
extraction form, accompanied by an operational definition of each
extracted variable. GW extracted all articles and MK extracted a
randomly chosen 10% of the articles. GW and MK then
compared the extraction results from the 10% articles. Disagree-
ments occurred in seven articles and in three of 38 variables. The
cause of the disagreements was the interpretation on vague
information listed in the articles. We then decided that only a
literal extraction was allowed, thus disallowing interpretation
during extraction. For example for the degree of blinding, if only
the description on how the investigator did the blinding but no
clear terms e.g. double blind were written in the articles, we
categorized it as ‘ambiguously stated’. We then updated the
operational definition accordingly and GW rechecked the
extraction results of those three variables in all the articles again
and if necessary revised them.
For any missing information, if the articles referred to a
registration database or previous paper for full description of the
methods, information from these sources was retrieved.
Table 1. The requirements in the guidelines for conducting and reporting NI trials.
Issues in NI trials Requirements in the guidelines
Blinding method - Blinding is necessary to minimize bias (ICH E9 and E10)It is critical to provide reassurance and procedures that ensure
maintenance of blinding (draft FDA guideline on NI trial 2010)
NI margin - An acceptable non-inferiority margin should be defined (ICH E10, CPMP/EMEA 2000)
- Should be pre-specified, and can be no larger than the presumed entire effect of the active control in the NI trial (draft FDA
guideline on NI trial 2010)
- Should be specified in publication (CONSORT statement extension, 2006)
Method to determine NI margin - The determination of the margin in a non-inferiority trial is based on both statistical reasoning and clinical judgment (ICH E10)
- Margin is chosen by defining the largest difference that is clinically acceptable, so that a difference bigger than this would
matter in practice (CPMP/EMEA 2000)
- The NI margin should be generally identified based on previous experience in placebo-controlled trials of adequate design
under conditions similar to those planned for the current trial, but could also be supported by dose response or active control
superiority studies.(ICH E10, CHMP/EMEA 2005)
- Fixed margin method (two CIs method) is recommended. It is referred to as fixed because the past studies comparing the
drug with placebo are used to derive a single fixed value for statistical margin, even though this value is based on results of
placebo-controlled trials (one or multiple trials versus placebo) that have a point estimate and confidence interval for the
comparison with placebo. This approach is relatively conservative, as it keeps separate the variability of estimates of the
treatment effect in the historical studies and the variability observed in the NI trial, and uses a fixed value for the estimate of
the control effect based on historical data (the 90% or 95% CI lower bound), a relatively conservative estimate of the control
drug effect. (draft FDA guideline on NI trial 2010)
- should be specified in publication (CONSORT statement extension, 2006)
Type of statistical analysis - Use of the full analysis set is generally not conservative and its role should be considered very careful (ICH E9)
- Both ITT and PP have equal importance (CPMP/EMEA 2000)
- Important to conduct both ITT and as-treated analyses. Differences in results using the two analyses will need close
examination. (draft FDA guideline on NI trial 2010)
Assay sensitivity - A trial should have the ability to distinguish an effective from an ineffective drug (ICH 10, draft FDA guideline on NI trial 2010)
- A three-armed trial with test, reference and placebo allows some within-trial validation of the choice of non-inferiority margin
and should be used wherever possible.(CHMP/EMEA 2005, draft FDA guideline on NI trial 2010)
Constancy assumption - The similarity of the new trial to the historical trial should be sufficient (CHMP/EMEA 2005, draft FDA guideline on NI trial 2010)
Similarity with trial of reference
treatment
- The report should contain whether the eligibility criteria, interventions and outcomes are identical (or very similar) to that of
any trial that established efficacy of the reference treatment (CONSORT statement extension, 2006)
Note: The draft FDA guideline is not in effect yet and still open for changes (as per 18
th March 2010).
doi:10.1371/journal.pone.0013550.t001
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From each article, we extracted information on the journals’
impact factor, type of drug, phase of the trial, trial’s sponsor
(independent investigator, pharmaceutical industry, or govern-
ment), trial’s design, primary endpoints, sample size, and the trial’s
conclusion of the new drug.
In addition, we extracted specific information whether the
authors mentioned any additional benefit of the new drug and
whether the additional benefit was addressed in the trial. For
example, if the author mentioned that the additional benefit of the
new drug was its better safety profile, we evaluated whether any
formal safety profile comparison was included in the results section
of the article.
We classified the journals based on their impact factor listed in the
JournalCitationReportsH(JCR)2008edition.Wearbitrarilychosea
cut-off point of ten to classify the journal as high or low-impact.
We extracted the phase of the trial according to the statement
in the publications or the referred clinical-trial’s database e.g.
clinicaltrials.gov.TheclassificationwasPhaseI,II,III,andIV.Phase
II and III might be divided into 2 parts, A and B. Phase IIA’s
primary aims are assessment and exploration of efficacy and
pharmacodynamic aspects of the drug in patients with the target
disease. In phase IIB, the main objectives are to confirm efficacy in a
relatively large group of patients and determine optimal dose and
dosing regimen to be implemented in phase III trials. In phase III
trials, the mainobjectives are to confirmand to gather the additional
information about the effectiveness and safety of the drug that are
needed to evaluate the overall benefit-risk profile of the drug. Phase
IIIA is conducted prior to application for marketing authorization,
while phase IIIB is conducted after application. [14,15]
We classified the type of primary endpoints as hard endpoints,
intermediate endpoints and subjective endpoints. Hard endpoints
were direct clinical events, such as mortality or stroke; interme-
diate endpoints were indirect outcome measurements that might
not necessarily have a direct relationship with the clinical event
such as laboratory data or biomarkers; and subjective endpoints
are endpoints based on subjective perspectives of investigator or
patient, such as quality-of-life questionnaires.
We extracted from the article specific characteristics of NI trials:
degreeofblinding,themethod to determinetheNImargin,thetype
of analysis, the use of a placebo arm to confirm assay sensitivity, and
whether the authors discussed the constancy assumption. Further-
more, we extracted reasons for not including a placebo arm.
In terms of blinding, we extracted the literal term reported by
the authors in the manuscript and classified the blinding into open-
label, single, double, triple and ‘‘ambiguously stated’’ blinding.
Figure 1. Flow diagram of trials’ selection process.
doi:10.1371/journal.pone.0013550.g001
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drugs, we assessed within these trials whether their NI margin was
consistent with them. Based on a guideline of the FDA (1992) and
CPMP (1997), the recommended NI margin for anti-infective
drugs is percentage difference of 10–20%.
We analyzed the quality of conducting NI trials by comparing
the design and analysis characteristics of the trials reported in the
high-impact vs. low-impact journals; and between the trials that
were sponsored by industry and non-industry.
Quality of reporting
To evaluate the quality of reporting, we compared the
requirements from the extension of the CONSORT statement
for NI and equivalence trials[10] between articles published before
and after 2006 to evaluate the impact of the CONSORT state-
ment extension on the reporting of NI trials. According to the
extension of the CONSORT statement for NI trials, the method
section should include additional information on how identical the
inclusion and exclusion criteria, type of interventions and
outcomes to previous efficacy trial of the active comparator were.
The additional information should also include the NI margin and
the method to determine it, sample size calculation, and whether a
one-sided or two-sided confidence interval (CI) was used. The side
of the CI is important in an NI trial as its inference of non-
inferiority is based on the CI of the treatment difference between
the test drug and its comparator. NI is concluded when the CI
excludes and lays beyond the NI margin.[11] Furthermore, we
compared the compliance to the CONSORT statement exten-
sion’s requirements between trials reported in the high-impact and
low-impact journals; and between the trials that were sponsored by
industry and non-industry.
Data analysis
Data were entered into a database using Epidata 3.1 (EpiData
Association, Odense, Denmark; www.epidata.dk) and all statistical
analyses were performed using SPSS 16 (SPSS Inc, USA; www.
spss.com). The p-values for the differences were calculated using
the Chi-square or Fischer’s Exact test.
Results
Selection of the trials
The selection process of the NI trials is outlined in Figure 1.
After filtering the articles based on the exclusion criteria, we
included 227 articles in the analysis, which referred to 232 trials.
One hundred eleven (47.8%) trials were published after 2006, the
year in which the extension of the CONSORT statement on NI
trials was published.
The missing data we retrieved from the registry were mostly
data on the trial’s phases and sponsorship. We only referred to the
database as suggested by the author, so we believe the data in the
register were reliable. We retrieved data of 34 trial’s phases from
clinicaltrial.gov; data of one trial’s phase and data of one trial’s
sponsor from ISCRTN; data of one trial’s sponsor from WHO
international clinical trial registry; and data of one trial’s phase
from a sponsor clinical-trial registry website.
The general characteristics of the trials
The general characteristics of the trials are described in Table 2.
Most of the trials were published in low-impact journals (84.5%).
Anti-infective drugs were the most studied drugs (22.9%).
Almost one-third (29.7%) of the studies were phase III studies
and the majority had pharmaceutical industry involvement in their
trial process (73.7%).
Almost all studies had a parallel design (93.1%), and both
hard and intermediate endpoints were often investigated.
Variability between studies in the ratio of number of subjects in
the analysis population versus the planned number of subjects
was considerable. Most of the trials concluded that the new drug
was shown to be non-inferior compared with its comparator (209
trials – 90.1%).
Table 2. The general characteristics of trials.
Number (%) unless
stated otherwise
Published in high-impact factor journals 46 (19.8)
Type of drug
Anti infective drugs 53 (22.9)
Cardiovascular and thrombolytic drugs 40 (17.2)
Drugs for endocrine disorders 26 (11.2)
Vaccines 24 (10.4)
Anti inflammatory and anti rheumatics drugs 17 (7.3)
Respiratory drugs 16 (6.9)
Neurological and psychiatric drugs 14 (6.0)
Anticancer drugs 11 (4.7)
Others 31 (13.4)
Phase
Phase II 7 (3.0)
Phase III 69 (29.7)
Phase IV 12 (5.2)
Phase IIIB and IV 3 (1.3)
Not stated 141 (60.8)
Sponsor
Independent investigator 39 (16.8)
Pharmaceutical industry 171 (73.7)
Government 6 (2.6)
Combination of any above 2 (0.9)
Not clear 14 (6.0)
Design
Parallel 216 (93.1)
Cross-over 13 (5.6)
Factorial 2 (0.9)
Cluster-randomized 1 (0.4)
Primary endpoints
Hard endpoints 97 (41.8)
Intermediate endpoints 102 (44.0)
Subjective endpoints 33 (14.2)
Sample size (median, interquartiles range)
Number of planned subjects 388(242–673)
Number of subjects in ITT analysis divided
by number of subjects planned
1.1 (1–1.2)
Number of subjects in PP analysis divided
by number of subjects planned
1.0 (0.8–1.1)
Conclusion
Non-inferiority was shown 209 (90.1)
Non-inferiority was not shown 17 (7.3)
Not clear 6 (2.6)
doi:10.1371/journal.pone.0013550.t002
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advantages of the new drug. Most of the additional benefits
mentioned and addressed were in terms of the safety profile of the
drug, as shown in Table 4.
The quality of conducting NI trials
The design and analysis characteristics of the trials are described
in Table 3, while stratification according to journal impact factors
is shown in Table 5. Six journals did not have their impact factor
listed in the JCR 2008 edition and were not included in the
analysis. We found no significant difference in terms of trials’
characteristics between trials that were sponsored by pharmaceu-
tical industry or not (data not shown).
More than half of the trials were stated as double blinded, while
a substantial number (79, 34.0%) was open label. We found no
difference in terms of blinding method between trials that were
published in high-impact or low-impact journals.
We observed that 227 (97.8%) trials reported their NI margin in
the articles. Nevertheless, only 106 (45.7%) trials reported the
method by which the NI margin was determined. In 51 (22%)
trials, the margin was determined merely based on investigator’s
assumption. In 20 (8.7%) trials, the NI margins were obtained
from other publications or reviews. In 18 (7.7%) trials, the NI
margins were obtained from guidelines and in 17 (7.3%) trials the
NI margins were calculated by the investigators based on data
from previous trials. Among the last, 15 of them used a preserved
fraction of 50% or greater. We also found in 95 (40.9%) trials, the
authors mentioned that the NI margin was a clinical acceptable
margin. Among them three trials mentioned that the decision to
use the margin was validated by a panel of clinical experts. We
found no difference in terms of method to determine the NI
margin between trials that were published in high-impact or low-
impact factor journals.
Within 53 anti-infective trials, most of the trials (42, 77.8% of all
anti-infective trials) used an NI margin of percentage difference
between 10 to 20%. Only four trials used a NI margin less than
10% or more than 20%. In the rest of seven trials, six trials did not
use percentage difference as an NI margin, and in one trial, the NI
margin was not clear.
In terms of statistical analysis, most of the trials (127, 54.7%)
used either ITT or PP, while 97 (41.8%) trials used both ITT and
PP analysis. We found among the trials that used both ITT and PP
analysis, 94 of them concluded that the new drug was non-inferior
to its comparator. In 53 trials of the latest, the conclusions were
deducted from similar results of both ITT and PP analysis. In the
rest of the trials: 22 trials concluded non-inferiority based on the
results of their PP analysis; 18 trials were based only on the results
of their ITT analysis; while in three trials, it was not clear on which
analysis their conclusion was based. We found a significant
difference in terms of type of statistical analysis between the trials
published in high-impact and low-impact factor journals. Trials
published in the high-impact journals mostly used only ITT
analysis (54.3% of 46 trials), while in the low-impact journals, both
analysis methods were most frequently used (44.4% of 180 trials).
In our review, we observed that 210 trials (90.5%) did not
include a placebo arm to confirm assay sensitivity. Only 19 trials
mentioned the reason why a placebo arm was not included in
trials, and almost half of them were due to ethical reasons. We
observed that the inclusion of a placebo is quite common (28.6%)
in trials with neurology/psychiatric drugs. This is probably
because in this type of drugs, the constancy assumption will often
not hold, as the placebo effect in previous placebo-controlled trials
is difficult to rule out. In addition, we found no difference in terms
of using a placebo arm to confirm the assay sensitivity between
trials that were published in high-impact or low-impact factor
journals.
Table 3. Design and analysis characteristics.
Number (%)
Blinding method
Open-label 79 (34.0)
Single 18 (7.8)
Double 125 (53.9)
Triple 1 (0.4)
Ambiguously stated 9 (3.9)
Method to determine NI margin
Based on investigator’s assumption 51 (22.0)
Based on other publications or reviews 20 (8.7)
Based on guidelines 18 (7.7)
Calculated by the investigator based
on previous trial’s result
17 (7.3)
Not clear 126 (54.3)
Type of statistical analysis
Both ITT and PP 97 (41.8)
Only ITT 81 (34.9)
Only PP 46 (19.8)
Not clear 8 (3.5)
Including placebo-arm to confirm assay sensitivity 14 (6.0)
Discuss constancy assumption 9 (3.9)
doi:10.1371/journal.pone.0013550.t003
Table 4. Additional benefit of the new drug mentioned in the
publication.
%* N ,
Addressed
"
(% from N)
Better safety profile 45 (36.3) 43 (95.6)
Better method of administration 19 (15.4) 6 (31.6)
Better safety profile and method of administration 12 (9.7) 10 (83.3) {
Better method of administration and induce
higher patient’s compliance rate
12 (9.7) 5 (41.7) {
Better safety profile and induce higher patient’s
compliance rate
7 (5.6) 5 (71.4) 1
Induce higher patient’s compliance rate 6 (4.8) 3 (50.0)
Better method of administration and low cost 5 (4.0) 2 (40.0) ¥
Others than above 18 (14.5) 10 (55.6)
Note:
*Percentage is based on 124 trials that mentioned any additional benefit of the
new drugs irrespective of whether or not data were shown to support the
claim.
"The authors show any analysis or argument of the additional benefit.
{Three trials addressed both the safety profile and the method of
administration, six trials only addressed the safety profile, and one trial only
addressed the method of administration.
{One trial addressed both the method of administration and patient’s
compliance rate, and four trials addressed only the patient’s compliance rate.
1Four trials addressed both safety profile and patient’s compliance and one trial
only addressed the safety profile.
¥One trial addressed both better method of administration and cost and one
trial only addressed cost.
doi:10.1371/journal.pone.0013550.t004
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the constancy assumption and there was no difference in this
respect between trials that were published in high-impact or low-
impact journals.
Compliance in reporting NI trials
Only 3.0% of the trials reported the similarity of the inclusion
and exclusion criteria with previous trials studying the effect of the
active comparator, 5.6% of the trials reported the similarity of the
type of intervention with previous trials, and 3.4% of the trials
reported the similarity of the outcomes. Seventy-seven (33.2%)
trials did not report whether they were going to present the data
using one-sided or two-sided CI in the methods section as required
by the CONSORT statement. Furthermore, we found that the
papers in low-impact journals reported the side of the CI more
frequently than those in the high-impact factor journals, and the
difference was significant (Table 6).
The compliance in reporting the items required by the
extension of the CONSORT statement before and after 2006 is
described in Table 6. We did not observe improvement of
reporting after the release of the CONSORT statement extension
for NI trials. The method of determination of the NI margin was
even reported less frequently in trials published after 2006 than in
trials published before and in 2006.
Discussion
In this review, we found five main issues in the design, analysis
and reporting of NI trials. First, many of the trials were open label
Table 5. Stratification of the articles according to their journal impact factors.
Trials’ design and analysis issues High-impact (N =46) Low-impact (N=180) p value
N (%)
Blinding method 0.11
Open-label 20 (43.5) 56 (31.1)
Single 5 (10.9) 12 (6.7)
Double 18 (39.1) 105 (58.3)
Triple 0 (0) 1 (0.6)
Ambiguously stated 3 (6.5) 6 (3.3)
Method to determine NI margin 0.34
Based on investigator’s assumption 16 (34.8) 35 (19.4)
Based on other publications or reviews 5 (10.9) 14 (7.8)
Based on guidelines 2 (4.3) 16 (8.9)
Calculated by the investigator based on previous trial’s result 3 (6.5) 14 (7.8)
Not clear 20 (43.5) 101(56.1)
Type of statistical analysis 0.01
Both ITT and PP 14 (30.4) 80 (44.4)
Only ITT 25 (54.3) 56 (31.1)
Only PP 6 (13.2) 39 (21.7)
Not clear 1 (2.1) 5 (2.8)
Including placebo-arm to confirm assay sensitivity 2 (4.3) 12 (6.7) 0.74
Discuss constancy assumption 1 (4.3) 7 (8.9) 0.65
doi:10.1371/journal.pone.0013550.t005
Table 6. Comparison of reporting of essential information in NI trials.
Reported in the method section
of a NI article Between High-impact journals and low-impact journals Before and after CONSORT statement in 2006
Percentage of trials p-value Percentage of trials p-value
High-impact (N=46) Low-impact (N=180)
Before and until 2006
(n=121)
After 2006
(n=111)
Eligibility similarity 2.2% 2.8% 1.00 2.5% 3.6% 1.00
Type of Intervention similarity 10.9% 3.9% 0.07 5.8% 5.4% 0.90
Outcomes similarity 4.3% 2.8% 0.63 2.5% 4.5% 1.00
NI margin 97.8% 98.3% 1.00 97.5% 98.2% 1.00
Method to determine NI margin 56.5% 43.9% 0.12 50.4% 40.5% 0.15
Side of CI 50.0% 71.7% ,0.01 64.5% 69.4% 0.26
doi:10.1371/journal.pone.0013550.t006
Non-Inferiority Trials Review
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13550trials. Second, reporting the method to determine the NI margin
was infrequent and limited. Third, most of the trials analyzed their
data with one statistical analysis method; ITT or PP. Fourth, we
observed that only few trials included a placebo-arm to confirm
assay sensitivity and that only few trials discussed the constancy
assumption. Lastly, we did not observe any difference in terms of
reporting in NI trials published before or after the release of the
extension of the CONSORT statement for NI trials in 2006.
In our review, about a third of the trials were open label trials.
This surprising finding was not consistent with the guidelines[8,11]
that suggest to use blinding whenever possible to minimize the risk
of bias. This leads to discussion on the importance of blinding in
an NI trial. Snappin believes that blinding only gives minor
protection in NI trials, since a blinded investigator with a
preliminary belief in non-inferiority of the test drug can bias the
result by assigning similar ratings to the treatment responses of all
patients. [16] There is no doubt, however, that blinding does offer
protection against information bias. In addition, there will usually
be endpoints (e.g. safety) for which differences are expected and for
which blinding will ensure stronger evidence. We therefore
conclude that blinding is still important in NI trials to avoid bias.
If blinding is not possible, subjective endpoints need to be avoided
and more stringent monitoring should be conducted.
The method to determine the NI margin was not reported in
more than half of the trials. This finding is consistent with previous
reviews in 2005 to 2006, where the methods were presented in
46% or less of the trials.[17,18,19] Apparently, the extension of
the CONSORT statement in 2006 has not brought any significant
impact yet. Furthermore, the statement has suggested that the NI
margin should be preferably justified on clinical grounds and its
relation to the effect of the reference treatment relative to placebo
in any previous trials should be noted.[10] We found that most of
the authors included a statement that the NI margin was a
clinically acceptable difference, but only three trials mentioned
that the margin was validated by a panel of clinical experts. This
finding was consistent with other reviews[17,18,19], where many
trials claimed that their margin was clinically relevant without any
clear details how the clinically acceptable NI margin was chosen.
Putting merely a statement that the margin was determined based
on clinically acceptable difference is not sufficient for any sub-
sequent trial replications. Thus, more details are needed in the
description on how the NI margin was determined. Furthermore,
a detailed description on how the margin was determined can help
the reader to decide whether the NI margin and the rationale for
the margin’s choice influenced the validity of the results.
We observed in anti-infective drug trials, that most of them used
a constant difference of 10–20% in treatment difference as their
NI margin. Regulators recommend an NI margin of 10% for
vaccines and anti-bacterials. [20,21] This margin of 10% is
acceptable as long as the primary outcome of interest has a high
incidence rate. The implication of using a 10% constant margin in
vaccines and anti-infective drugs should be further explored and
any improvement on the guidelines to determine NI margin
should cover this issue.
We observed that most of the trials reported the result only from
ITT analysis or PP analysis. Our results were consistent with a
previous review that observed that more NI trials used ITT rather
than PP.[18] We also observed that ITT analysis was more
reported in high-impact journals. The CPMP guidelines and the
new draft FDA guidelines for NI trials already stated that both
analyses have equal importance in NI trials. For superiority trials,
ITT analysis is the preferred analysis as it adheres to randomi-
zation [11] and might best reflect clinical practice. PP analysis
might violate randomization and not reflect clinical practice very
well. Several reviews with RCT simulation showed that both ITT
and PP could be problematic in NI trials, especially if the trial had
large number of non-compliance.[22,23,24] In addition, in our
data, we did not observe any evidence that ITT will lead to more
NI conclusions than PP. We conclude that both analyses are
equally important, as each approach brings a different interpre-
tation for the drug in daily practice.
We observed that only a small number of trials included placebo
arms to support assay sensitivity. Although our data did not
provide sufficient evidence whether the use of placebo was
appropriate or not in the trials, we believe that the use of a
placebo arm was probably not ethically feasible in most studies.
Nonetheless, the non-inferiority result of the drugs in NI trials
might bear two meanings: both drugs are equally effective, or both
drugs are equally ineffective against placebo. In this sense, a
placebo arm in an NI trial will enable evaluation whether both
drugs in the trial are effective, if the trial shows non-inferiority.
Alternatively, if the use of a placebo arm is not possible, the trial
should choose a margin that assures that the estimated effect of the
new drug is likely to be superior to placebo, under the constancy
assumption for the active comparator. The readers, not only the
investigators, also need to be aware of this issue of assay sensitivity
in interpreting the result of NI trials. They need to consider the
type of endpoints; the number of patients in the final analysis;
reasons of patient’s dropouts; the similarity of the trial with the
previous trial(s) that established the efficacy profile of the com-
parator; and the constancy assumption of the data used as
reference for the NI margin. Based on our review, two of the latter
were only being reported in a small numbers of the articles.
Less than five percent of the trials in our review mentioned
whether the trials were designed similar to relevant past trial(s).
Thus, it was difficult to assess whether the historical data that were
used for determining the NI margin were reliable. Since the
validity of the NI margin is related to the interpretation of the NI
trials, clear reporting of the method of NI margin determination
and the constancy assumption is essential for every NI trial
publication. It is impossible to check the validity of the constancy
assumption without a parallel placebo arm. However, at
minimum, it is possible to check whether the current NI trial
was similar to previous trial(s) that estimated the efficacy of the
active comparator. [25]
We found no difference between reporting before and after the
release of the extension of the CONSORT statement on NI trials.
Furthermore, in general, there is no difference in adherence to the
CONSORT statement between the high-impact and the low-
impact journals. The overall low adherence to the statement might
be due to unfamiliarity of the authors, referees, and editors of all of
the journals with the statement extension. Researchers and editors
of journals should be more aware of this extension and should
comply with its recommendations. We realized that it might be too
early to see full adherence of the CONSORT statement exten-
sion after 3 years, but due to the reputation of the CONSORT
statement itself, we considered it reasonable to expect a certain
degree of improvement.
Our review has some limitations. First, we excluded several
trials since we only used a random sample of all NI trials that we
identified. However, as this was a random sample, this will not
have influences our results. Second, we only used PubMed to
identify NI trials; therefore, we might have missed some trials.
However, we assume that NI trials retrieved from PubMed do not
have different methodological characteristics than NI trials in
other databases, so we do not think that this influenced our results.
Third, since the terms that we used to search for non-inferiority
trials were not standard MESH terms and our search for those
Non-Inferiority Trials Review
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not have captured all NI drug trials available in PubMed. Also for
this selection, we expect that the NI trials that we found are not
different from the NI trials that we did not capture with our
search. A strength of our study is that we did not only focus on the
NI margin, as previous reviews[17,18,19] did, but also evaluated
other methodological aspects of NI trials. In addition, we
evaluated the quality of reporting using the current guidelines
from the CONSORT statement.
In conclusion, the conduct and reporting of NI trials can be
further improved. Particularly, in terms of maximizing the use of
blinding, the use of both ITT and PP analysis, reporting the
similarity with the previous comparator’s trials to guarantee a valid
constancy assumption and reporting the method to determine NI
margin.
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